BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hummingbird Bioscience readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hummingbird Bioscience's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06956690-2470@assetmemo.bio
DTSTAMP:20261121T005805Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:ENV-501: Phase 1/2 readout est. (NCT06956690)
DESCRIPTION:ENV-501\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2 Clinical Trial to Assess the Safety\, Tolerability\, Pharmacokineti
 cs and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing S
 olid Tumors\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/env-501#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06956690
URL:https://assetmemo.bio/drug/env-501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-2517@assetmemo.bio
DTSTAMP:20261121T005805Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nezutatug: Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Nezutatug\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cetuximab +/- 
 Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nez
 utatug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05910827
URL:https://assetmemo.bio/drug/nezutatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
